Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 301–400 of 1,000
Pulmonary Hypertension Due to Left Heart Disease—A Practical Approach to Diagnosis and Management
Lee, F., & Mielniczuk, L. M. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.11.003 · Cited by 22
Butler, J., Djatche, L. M., Lautsch, D., Yang, L., Patel, M. J., & Mentz, R. J. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.06.019 · Cited by 21
Self-citationCalcium and Heart Failure: How Did We Get Here and Where Are We Going?
Siri‐Angkul, N., Dadfar, B., Jaleel, R., Naushad, J., Parambathazhath, J., Doye, A. A., Xie, L., & Gwathmey, J. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147392 · Cited by 21
Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
Rahamim, E., Nachman, D., Yagel, O., Yarkoni, M., Elbaz‐Greener, G., Amir, O., & Asleh, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194409 · Cited by 24
Herzinsuffizienzleitlinien 2021 der ESC
Bauersachs, J. K., & Soltani, S. (2021) · Herz · doi:10.1007/s00059-021-05084-5 · Cited by 23
“Vericiguat kann bei Patienten mit einer HFrEF und kürzlicher Hospitalisierung aufgrund einer Dekompensation das Outcome verbessern [4] und hält mit einer Klasse-IIb-Indikation Einzug in die Leitlinien.”
BackgroundEndpoints in Heart Failure Drug Development
Hussain, A., Misra, A., & Bozkurt, B. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.13 · Cited by 23
“1016/S0140-6736(20)30635-8; PMID: 32534650.”
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction
Greenberg, B. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0401 · Cited by 26
Improving implementation of evidence‐based therapies for heart failure
DeVore, A. D., Bosworth, H. B., & Granger, B. B. (2022) · Clinical Cardiology · doi:10.1002/clc.23845 · Cited by 22
Gallo, G., Rubattu, S. D., Autore, C., & Volpe, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065131 · Cited by 25
“Compared to the placebo, vericiguat significantly reduced the primary composite outcome of death from cardiovascular causes or first hospitalization for HF (−10%), the secondary endpoints of total hospitalizations for HF (−9%), and death from any cause or first hospitalization for HF (−10%) [102].”
BackgroundVericiguat attenuates doxorubicin-induced cardiotoxicity through the PRKG1/PINK1/STING axis
Zeng, X., Zhang, H., Xu, T., Mei, X., Wang, X., Yang, Q., Luo, Z., Zeng, Q., Xu, D., & Ren, H. (2024) · Translational research · doi:10.1016/j.trsl.2024.07.005 · Cited by 22
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment
Madonna, R., Biondi, F., Ghelardoni, S., D'Alleva, A., Quarta, S., & Massaro, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.030 · Cited by 24
ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy
Fusco, S. A. D., Alonzo, A., Aimo, A., Matteucci, A., Intravaia, R., Aquilani, S., Cipriani, M., de Luca, L., Navazio, A., Valente, S., et al. (2023) · European Heart Journal, Supplement · doi:10.1093/eurheartjsupp/suad106 · Cited by 17
“14 The incidence of adverse events, such as symptomatic hypotension and syncope, was similar in the two groups, confirming the good safety profile of the drug.”
BackgroundMethodResultOkami, S., Ohlmeier, C., Takeichi, M., Aguila, M., Holl, K., Michel, A., Lecomte, C., & Ide, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113222 · Cited by 21
“The VICTORIA randomized controlled trial evaluated the efficacy and safety of vericiguat among patients with HF with reduced ejection fraction (HFrEF) who experienced a worsening of HF [13].”
MethodFluid Restriction for Patients with Heart Failure: Current Evidence and Future Perspectives
Kato, N., Nagatomo, Y., Kawai, F., Kitai, T., & Mizuno, A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070741 · Cited by 23
“Irrespective of its neutral effect on these, vericiguat was shown to cause significant improvement of hemodynamics, including reduced pulmonary artery wedge pressure [72], and was shown to be effective in reducing cardiovascular death or ADHF hospitalization of patients with HFrEF [73].”
BackgroundTian, J., Dong, M., Sun, X., Jia, X., Zhang, G., Zhang, Y., Lin, Z., Xiao, J., Zhang, X., & Lu, H. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132524 · Cited by 20
Gu, Z., Liu, T., Rao, W., Li, D., Zhang, Q., Dai, J., Huang, L., Wang, J., & Hou, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202412335 · Cited by 20
Gawryś, O., Kala, P., Sadowski, J., Melenovský, V., Sandner, P., & Červenka, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177175 · Cited by 23
Heart Failure in Older Patients: An Update
Montalto, M., D'Ignazio, F., Camilli, S., Francesco, S. D., Fedele, M., Landi, F., & Gallo, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061982 · Cited by 26
“The results of the VICTORIA study demonstrated that vericiguat reduces cardiovascular mortality and hospitalizations due to heart failure, although the benefits vary among different patient subgroups [147].”
Cardiac fibrosis: emerging agents in preclinical and clinical development
Spoladore, R., Falasconi, G., Fiore, G., Maio, S. D., Preda, A., Slavich, M., Margonato, A., & Fragasso, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868432 · Cited by 21
Das, B. B., Moskowitz, W. B., & Butler, J. (2021) · Children · doi:10.3390/children8050322 · Cited by 22
“In the VICTORIA trial, adult patients with chronic symptomatic HF and an ejection fraction of <45% had a reduced risk of cardiovascular death, all-cause death, and HF hospitalization [60].”
BackgroundSelf-citationBöettcher, M., Mikus, G., Trenk, D., Düngen, H., Donath, F., Werner, N., Karakas, M., Besche, N., Schulz‐Burck, D., Gerrits, M., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13238 · Cited by 19
Danielson, C., Lileikyte, G., Ouwerkerk, W., Lam, C. S. P., Erlinge, D., & Teng, T. K. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13974 · Cited by 27
“Foundational treatments recommended for heart failure (HF) with reduced ejection fraction (HFrEF) comprise of reninangiotensin system inhibitors (RASi), which include angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB); angiotensin receptorneprilysin inhibitors (ARNi); beta-blockers…”
BackgroundResultInfluentialSelf-citationMechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 22
Self-citationGetting ahead of the game: in-hospital initiation of HFrEF therapies
Biegus, J., Moayedi, Y., Saldarriaga, C., & Ponikowski, P. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac120 · Cited by 21
“This was a multinational, randomized, double-blind, placebo-controlled trial, which recruited stable, ambulatory chronic HFrEF (EF < 45%), NYHA class II–IV patients who had recently been hospitalized or had received intravenous diuretic therapy.(54) The drug was not initiated during the hospitalization, but most patie…”
MethodResultSelf-citationSingh, H., Agarwal, L., Jani, C., Bhatt, P. S., Hartley, A., Shalhoub, J., Kurman, J. S., Omari, O. A., Ahmed, A., Marshall, D. C., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1468 · Cited by 21
Ezekowitz, J. A., Alemayehu, W. G., Edelmann, F., Ponikowski, P. P., Lam, C. S. P., O’Connor, C. M., Butler, J., Corda, S., McMullan, C. J., Westerhout, C. M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3179 · Cited by 20
Self-citationHeart failure management with β-blockers: can we do better?
de Oliveira, M. T., Baptista, R., Leal, S., & Bonatto, M. G. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2318002 · Cited by 23
“Soluble guanylate cyclise inhibitors may hold promise for improving outcomes in people with HFrEF in the future: for example, vericiguat was effective in improving outcomes in patients with deteriorating HFrEF 8 , although this agent did not improve quality of life in patients with HFpEF 9 .”
BackgroundWu, Y., Zou, Y., Song, C., Cao, K., Cai, K., Chen, S., Zhang, Z., Geng, D., Zhang, N., Feng, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117093 · Cited by 22
Hashimoto, T., Yoshitake, T., Suenaga, T., Yamamoto, S., Fujino, T., Shinohara, K., Matsushima, S., Ide, T., Kinugawa, S., & Abe, K. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132441 · Cited by 19
Ezekowitz, J. A., Mentz, R. J., Westerhout, C. M., Sweitzer, N. K., Givertz, M. M., Piña, I. L., O’Connor, C. M., Greene, S. J., McMullan, C. J., Roessig, L., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008242 · Cited by 19
Self-citationAn introduction to therapeutic approaches to vascular cognitive impairment
Hainsworth, A. H., Elahi, F. M., & Corriveau, R. A. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100033 · Cited by 25
Upcoming drug targets for kidney protective effects in chronic kidney disease
Nardone, M., Yau, K., Kugathasan, L., Odutayo, A., Mohsen, M., Ouimet, J.-P., Sridhar, V. S., & Cherney, D. Z. I. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae216 · Cited by 25
“In a large cardiovascular outcome trial, the sGC stimulator vericiguat reduced the incidence of death from cardiovascular causes or hospitalization for heart failure compared with placebo [53 ].”
Worsening heart failure: progress, pitfalls, and perspectives
Fonseca, C., Rui, B., Franco, F., Brenda, M., Pimenta, J., Sarmento, P., Silva‐Cardoso, J., & Brito, D. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10497-z · Cited by 25
“Compared with other HFrEF landmark trials (38.5%, 39.1%, and 76.3% in the VICTORIA, GALAC-TIC-HF, and SOLOIST-WHF trials vs. 26.5%, 21.2%, and 24.7%, in the PARADIGM-HF, DAPA-HF, or EMPEROR-REDUCED trials) [107–109, 118, 122, 124].”
InfluentialSoluble guanylyl cyclase: Molecular basis for ligand selectivity and action in vitro and in vivo
Wu, G., Sharina, I. G., & Martin, E. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1007768 · Cited by 23
“Some of these stimulators, such as riociguat and vericiguat have been approved for treatment of conditions of pulmonary hypertension and heart failure, respectively (Ghofrani et al., 2013a; Ghofrani et al., 2013b; Armstrong et al., 2020).”
BackgroundVericiguat: A New Hope for Heart Failure Patients
Chiles, R., & Al-Horani, R. A. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/1554875 · Cited by 17
“2% annualized absolute risk reduction with the drug compared with placebo, over the study course [17].”
BackgrounddeFilippi, C. R., Alemayehu, W. G., Voors, A. A., Kaye, D. M., Blaustein, R. O., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., Roessig, L., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.12.013 · Cited by 18
Self-citationChronic Heart Failure in Children: State of the Art and New Perspectives
Castaldi, B., Cuppini, E., Fumanelli, J., Candia, A. D., Sabatino, J., Sirico, D., Vida, V. L., Padalino, M. A., & Salvo, G. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072611 · Cited by 19
“In a recent trial, VICTORIA, a number of 5050 adult patients with chronic symptomatic HF and an ejection fraction of <45% had a reduced risk of cardiovascular death, all-cause death, and HF hospitalization [29].”
BackgroundDucharme, A., Zieroth, S. R., Ahooja, V., Anderson, K., Andrade, J. G., Boivin‐Proulx, L., Ezekowitz, J. A., Howlett, J. G., Lepage, S., Leong, D., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.022 · Cited by 25
Self-citationNew Therapeutics for Heart Failure: Focusing on cGMP Signaling
Mangmool, S., Duangrat, R., Parichatikanond, W., & Kurose, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612866 · Cited by 21
“Results of larger phase III clinical trials showing the efficacy of vericiguat in HFrEF patients were published in 2020 [66,140].”
BackgroundMethodInfluentialΠαπαθανασίου, Μ., Ruhparwar, A., Kamler, M., Rassaf, T., & Luedike, P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107619 · Cited by 18
Merkaš, I. S., Slišković, A. M., & Lakušić, N. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i7.183 · Cited by 23
Kidney function assessment and endpoint ascertainment in clinical trials
Khan, M. S., Bakris, G. L., Packer, M., Shahid, I., Anker, S. D., Fonarow, G. C., Wanner, C., Weir, M. R., Zannad, F. M., & Butler, J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab832 · Cited by 19
Self-citationCarrizales‐Sepúlveda, E. F., Ordaz‐Farías, A., Vargas-Mendoza, J. A., Vera‐Pineda, R., & Flores‐Ramírez, R. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.20 · Cited by 21
“66,67 Although in-depth discussion of such patient profiles and the available options for treatment is beyond the scope of this review, some detailed reviews and position statements are available.”
BackgroundAngiotensin II-Induced Cardiovascular Fibrosis Is Attenuated by NO-Sensitive Guanylyl Cyclase1
Broekmans, K., Giesen, J., Menges, L., Koesling, D., & Russwurm, M. (2020) · Cells · doi:10.3390/cells9112436 · Cited by 17
“Recently, a clinical trial with an NO sensitiser/NO-GC stimulator in the treatment of heart failure with reduced ejection fraction has been completed [22].”
BackgroundBöettcher, M., Düngen, H., Donath, F., Mikus, G., Werner, N., Thürmann, P., Karakas, M., Besche, N., Koch, T., Gurniak, M., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2574 · Cited by 17
“20 However, although symptomatic hypotension and syncope were more common in patients receiving vericiguat than in those receiving placebo in the VICTORIA study, the difference in frequency between groups was not significant.(9) Distribution of TEAEs was similar in both treatment groups and most were classified as mil…”
BackgroundResultGellen, B., Thorin‐Trescases, N., Thorin, É., Gand, E., Ragot, S., Montaigne, D., Pucheu, Y., Mohammedi, K., Gatault, P., Potier, L., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14036 · Cited by 16
“The 1000 pg/mL threshold, arbitrary and by definition imperfect, was based on inclusion criteria used in recent large HF studies.(26,27) Second, although S100A12 predicted a higher risk of HHF, S100A12 concentrations were not significantly higher (P = 0.”
MethodChimed, S., Stassen, J., Galloo, X., Meucci, M. C., Knuuti, J. M., Delgado, V., van der Bijl, P., Marsan, N. A., & Bax, J. J. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.06.058 · Cited by 19
Jungtanasomboon, P., Nussaro, S., Winwan, H., Suebthawinkul, P., Boonpala, P., Dong, V. N. K., Saengklub, N., Kumphune, S., Panyasing, Y., & Kijtawornrat, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121929 · Cited by 18
Targeting Soluble Guanylyl Cyclase during Ischemia and Reperfusion
Mace, E. H., Kimlinger, M. J., Billings, F. T., & Lopez, M. G. (2023) · Cells · doi:10.3390/cells12141903 · Cited by 19
A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure
Sahana, U., Wehland, M., Simonsen, U., Schulz, H., & Grimm, D. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411826 · Cited by 22
“In the vericiguat trials presented here, mixed model analyses are used to remove ethnic effects [47,56] or, in contrast, the vericiguat effect on patients was calculated separately for different ethnic groups, genders, and ages [48].”
MethodInfluentialZaher, W., Rocca, D. G. D., Pannone, L., Bovéda, S., de Asmundis, C., Chierchia, G., & Sorgente, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051316 · Cited by 18
“However, data specifically concerning SCD were not provided [113].”
BackgroundZhan, Y., Li, Q., Zhou, J., Ma, Y., Guan, X., Wang, S., & Ya, C. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04477-2 · Cited by 17
New Targets in Heart Failure Drug Therapy
Correale, M., Tricarico, L., Fortunato, M., Mazzeo, P., Nodari, S., Biase, M. D., & Brunetti, N. D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.665797 · Cited by 17
“Vericiguat is a novel soluble guanylate cyclase (sGC) stimulator, tested in the SOCRATES PRESERVED study (16), REDUCED study (17), and recently also in the VICTORIA trial (18).”
MethodGuidelines for treating heart failure
Kittleson, M. M. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.10.002 · Cited by 19
Implications of Oxidative Stress in the Pathophysiological Pathways of Heart Failure
D’Amato, A., Cestiè, C., Ferranti, F., Segato, C., Prosperi, S., Germanò, R., Myftari, V., Bartimoccia, S., Castellani, V., Badagliacca, R., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115165 · Cited by 24
“The VICTORIA study [55], a randomized, placebo-controlled phase 3 clinical trial involving 5050 patients with chronic HFrEF, showed a significant reduction in the composite primary endpoint of cardiovascular death or first hospitalization for HF in patients receiving vericiguat compared to placebo.”
Kaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 19
Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia
Bork, N. I., Kuret, A., Santos, M. C., Molina, C. E., Reiter, B., Reichenspurner, H. C., Friebe, A., Skryabin, B. V., Rozhdestvensky, T. S., Kühn, M., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102179 · Cited by 15
Mentz, R. J., Lautsch, D., Pulungan, Z., KIM, S., Hilkert, R. J., Teigland, C. L., Yang, M., & Djatche, L. M. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.11.013 · Cited by 16
Vericiguat in heart failure: From scientific evidence to clinical practice
González‐Juanatey, J. R., Anguita-Sánchez, M. P., Bayés‐Genís, A., Colet, J. C., Quintana, A. G., Mayoral, A. R., Zamorano-Gómez, J. L., Cepeda-Rodrigo, J. M., & Manzano, L. (2022) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2021.12.006 · Cited by 21
Pharmacological developments in antihypertensive treatment through nitric oxide—cGMP modulation
Jüttner, A. A., Danser, A. H. J., & Roks, A. J. M. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.01.001 · Cited by 15
Sepehrvand, N., Islam, S., Dover, D. C., Kaul, P., McAlister, F. A., Armstrong, P. W., & Ezekowitz, J. A. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.04.015 · Cited by 17
Self-citationShakoor, A., Kamar, S. A., Malgie, J., Kardys, I., Schaap, J., de Boer, R. A., Mieghem, N. M. V., van der Boon, R. M. A., & Brugts, J. J. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3048 · Cited by 21
Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction
Zeitler, E. P., Johnson, A. E., Cooper, L. B., Steinberg, B. A., & Houston, B. A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.016 · Cited by 20
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
Chinese Society of Cardiology, C. M. A., Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, & Editorial Board of Chinese Journal of Cardiology (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000146 · Cited by 49
Hemodynamic Profiles and Their Prognostic Relevance in Cardiac Amyloidosis
Duca, F., Snidat, A., Binder, C., Rettl, R., Dachs, T., Seirer, B., Camuz-Ligios, L., Dusik, F., Capelle, C., Hong, Q., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041093 · Cited by 16
“, the time to the first occurrence of cardiovascular death or HF hospitalization [5].”
Pulmonary hypertension associated with left-sided heart failure
Adler, J., Gerhardt, F., Wißmüller, M., Adler, C., Baldus, S. E., & Rosenkranz, S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000791 · Cited by 19
Spall, H. G. C. V., Averbuch, T., Damman, K., & Voors, A. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2248 · Cited by 16
Self-citationDosunmu-Ogunbi, A. M., Galley, J. C., Yuan, S. S., Schmidt, H. M., Wood, K. C., & Straub, A. C. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.16493 · Cited by 20
Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure
Gidlöf, O. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.650124 · Cited by 19
Ameri, P., Marzo, V. D., Biondi‐Zoccai, G., Tricarico, L., Correale, M., Brunetti, N. D., Canepa, M., Ferrari, G. M. D., Castagno, D., & Porto, I. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab088 · Cited by 18
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
Pagnesi, M., Baldetti, L., Aimo, A., Inciardi, R. M., Tomasoni, D., Vizzardi, E., Vergaro, G., Emdin, M., & Lombardi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020348 · Cited by 18
“Furthermore, the SGLT2i trials included only 25–30% of patients with NYHA class III−IV [6,7], whereas the omecamtiv mecarbil and vericiguat trials included up to 45% of patients with NYHA III−IV [8,9].”
BackgroundMethodContemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
Vishram‐Nielsen, J. K. K., Tomasoni, D., Gustafsson, F., & Metra, M. (2022) · Drugs · doi:10.1007/s40265-021-01666-z · Cited by 19
“Vericiguat, a soluble guanylate cyclase stimulator, which acts by augmenting nitric oxide production, has been shown to reduce the incidence of death from CV causes or hospitalization for HF in patients admitted with HF, or recently discharged [137].”
BackgroundSantobuono, V. E., Favale, S., D'Onofrio, A., Manzo, M., Calò, L., Bertini, M., Savarese, G., Santini, L., Russo, A. D., Lavalle, C., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14416 · Cited by 17
Dasari, T. W., Csípő, T., Amil, F., Lipécz, Á., Fülöp, G., Jiang, Y., Samannan, R., Johnston, S. E., Zhao, Y. D., Silva-Palacios, F., et al. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.12.017 · Cited by 16
Kloepper-Sams, P. J., & Stegeman, J. J. (1994) · PubMed · Cited by 16
Lam, C. S. P., & Butler, J. (2020) · Circulation · doi:10.1161/circulationaha.120.048365 · Cited by 16
Self-citationWomen and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Center- vs Home-Based Cardiac Rehabilitation in Patients With Heart Failure
Schmidt, C., Magalhães, S., Basilio, P. G., Santos, C., Oliveira, M. I., Ferreira, J. P., Ribeiro, F., & Santos, M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.024 · Cited by 20
Ktenopoulos, N., Anagnostopoulou, L., Apostolos, A., Iliakis, P., Karakasis, P., Milaras, N., Theofilis, P., Fragoulis, C., Drakopoulou, M. I., Synetos, A. G., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47110886 · Cited by 21
“Importantly, the treatment showed no negative effects on blood pressure or renal function, underscoring its safety profile [164].”
Constitutive protein kinase G activation exacerbates stress‐induced cardiomyopathy
Schwaerzer, G. K., Casteel, D. E., Cividini, F., Kalyanaraman, H., Zhuang, S., Gu, Y., Dalton, N. D., Peterson, K. L., DILLMANN, W. H., Boss, G. R., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15530 · Cited by 17
“In heart failure with reduced ejection fraction, benefits were observed with PDE5 inhibitors and with the GC-1 activator vericiguat in some, but not all trials (Armstrong et al., 2020; Blanton, 2020; Burnett, 2020; De Vecchis et al., 2017).”
BackgroundDębska-Kozłowska, A., Książczyk, M., & Lelonek, M. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10120-x · Cited by 16
Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure
Campbell, N., Kalabalik-Hoganson, J., & Frey, K. M. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211041384 · Cited by 16
Krittayaphong, R., & Permsuwan, U. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01079-6 · Cited by 15
“The mortality rate was higher in patients with recent HF hospitalization than in those with chronic HF [5, 6].”
BackgroundArterial stiffness and pulsatile hemodynamics in heart failure
Chirinos, J. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91391-1.00036-4 · Cited by 15
Right Heart Function in Cardiorenal Syndrome
Kramer, T., Brinkkoetter, P. T., & Rosenkranz, S. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00574-x · Cited by 19
Implantable defibrillator‐detected heart failure status predicts ventricular tachyarrhythmias
Compagnucci, P., Casella, M., Bianchi, V., Franculli, F., Vitali, F., Santini, L., Savarese, G., Santobuono, V. E., Chianese, R., Lavalle, C., et al. (2023) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.15898 · Cited by 18
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 25
Bánfi‐Bacsárdi, F., Pilecky, D., Vámos, M., Majoros, Z., Török, G. M., Borsányi, T., Dékány, M., Solymossi, B., Andreka, P. G., Duray, G. Z., et al. (2024) · Clinical Cardiology · doi:10.1002/clc.24244 · Cited by 20
Quagliariello, V., Berretta, M., Bisceglia, I., Giacobbe, I., Iovine, M., Giordano, V., Arianna, R., Barbato, M., Izzo, F., Maurea, C., et al. (2024) · Cancers · doi:10.3390/cancers16081487 · Cited by 18
“It is used for the treatment of heart failure characterized by reduced ejection fraction (called HFrEF) [22].”
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Fritsch, A., Meyer, M. C., Blaustein, R. O., Trujillo, M. E., Kauh, E. A., Roessig, L., Böettcher, M., & Becker, C. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01384-1 · Cited by 18
“In the VICTORIA trial, the observed imbalance in symptomatic hypotension and syncope between the vericiguat and placebo groups was similar in patients with HFrEF taking sacubitril/valsartan versus those not taking sacubitril/valsartan [10, 11].”
BackgroundMethodResultInfluentialSelf-citationFujii, C., Hiraishi, M., Yamashita, K., Tsunamoto, H., Fujimoto, W., Odajima, S., Hirata, K., & Tanaka, H. (2024) · Circulation Reports · doi:10.1253/circrep.cr-24-0076 · Cited by 15
“BNP levels were significantly lower after initiation of vericiguat (427 [224–1,040] vs. 221 [92–466] pg/dL; P=0.012), while NT-proBNP levels tended to be lower (4,773 [1,584–12,330] vs. 4,035 pg/dL [780–7,503]; P=0.221).”
MethodInfluentialHeart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Latif, A., Lateef, N., Lundgren, S. W., Kapoor, V., Ahsan, M. J., & Aboeata, A. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100904 · Cited by 15
Mentz, R. J., Mulder, H. S., Mosterd, A., Sweitzer, N. K., Senni, M., Butler, J., Ezekowitz, J. A., Lam, C. S. P., Pieske, B. M., Ponikowski, P. P., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.05.016 · Cited by 16
Self-citationManagement of Pulmonary Hypertension in Left Heart Disease
Macera, F., & Vachiéry, J. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/rkqn5397 · Cited by 18
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Carnicelli, A., Clare, R. M., Hofmann, P., Chiswell, K., DeVore, A. D., Vemulapalli, S., Felker, G. M., Sarocco, P., & Mentz, R. J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.021276 · Cited by 16
Romano, E., Rosa, I., Fioretto, B. S., Giuggioli, D., Manetti, M., & Matucci‐Cerinic, M. (2022) · Rheumatology · doi:10.1093/rheumatology/keac433 · Cited by 18
Zhao, D., Zhang, Y., Yong, Y., Wang, L., & Liu, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1476976 · Cited by 15
“This leads to improvements in myocardial and vascular function, delays left ventricular remodeling, prevents or even reverses left ventricular hypertrophy, ultimately resulting in enhanced myocardial and vascular function (9 – 11).”
BackgroundMethodCarulli, E., Marozzi, M. S., Carella, M. C., Guaricci, A. I., Tarsia, G., Vacca, A., Desantis, V., & Cicco, S. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.02 · Cited by 18
“81 In particular, this trial demonstrated that vericiguat significantly reduced above-mentioned endpoints in high-risk HFrEF patients, with greater efficacy observed in those with lower baseline NT-proBNP levels, indicating less advanced disease.”
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.